Europe could recommend second biosimilar arthritis drug this week

LONDON (Reuters) - Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news